Company news

Rapport Therapeutics, Inc. news in 2026

Rapport Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update

November 4, 2026

Rapport Therapeutics to Participate in Upcoming Investor Conferences

November 3, 2026

Rapport Announces Closing of Public Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Notes, as well as Concurrent Private Placement

November 2, 2026

Rapport Announces Pricing of Underwritten Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes and Concurrent Private Placement

October 28, 2026

Rapport Announces Proposed Public Offerings of Common Stock and Convertible Notes as well as Concurrent Private Placement

October 27, 2026

Rapport Therapeutics Announces Positive Topline Results from its Phase 2 Trial of RAP-219 for the Treatment of Bipolar Mania

October 20, 2026

Rapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Clinical Program

August 24, 2026

Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update

August 5, 2026

Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference

May 20, 2026

Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update

May 7, 2026

Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual Meeting

April 21, 2026

Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting

March 31, 2026

Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

March 9, 2026

Rapport Therapeutics and Tenacia Biotechnology Announce Strategic Collaboration for the Development and Commercialization of RAP-219 in Greater China

March 8, 2026

Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline

January 6, 2026

Decks in 2026